Integrated Sustainable childhood Pneumonia and Infectious disease Reduction in Nigeria (INSPIRING) through whole system strengthening in Jigawa, Nigeria: study protocol for a cluster randomised controlled trial.
Child mortality
Cluster randomised controlled trial
Community
Nigeria
Participatory learning and action
Pneumonia
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
received:
01
06
2021
accepted:
22
11
2021
entrez:
1
2
2022
pubmed:
2
2
2022
medline:
3
2
2022
Statut:
epublish
Résumé
Child mortality remains unacceptably high, with Northern Nigeria reporting some of the highest rates globally (e.g. 192/1000 live births in Jigawa State). Coverage of key protect and prevent interventions, such as vaccination and clean cooking fuel use, is low. Additionally, knowledge, care-seeking and health system factors are poor. Therefore, a whole systems approach is needed for sustainable reductions in child mortality. This is a cluster randomised controlled trial, with integrated process and economic evaluations, conducted from January 2021 to September 2022. The trial will be conducted in Kiyawa Local Government Area, Jigawa State, Nigeria, with an estimated population of 230,000. Clusters are defined as primary government health facility catchment areas (n = 33). The 33 clusters will be randomly allocated (1:1) in a public ceremony, and 32 clusters included in the impact evaluation. The trial will evaluate a locally adapted 'whole systems strengthening' package of three evidence-based methods: community men's and women's groups, Partnership Defined Quality Scorecard and healthcare worker training, mentorship and provision of basic essential equipment and commodities. The primary outcome is mortality of children aged 7 days to 59 months. Mortality will be recorded prospectively using a cohort design, and secondary outcomes measured through baseline and endline cross-sectional surveys. Assuming the following, we will have a minimum detectable effect size of 30%: (a) baseline mortality of 100 per 1000 livebirths, (b) 4480 compounds with 3 eligible children per compound, (c) 80% power, (d) 5% significance, (e) intra-cluster correlation of 0.007 and (f) coefficient of variance of cluster size of 0.74. Analysis will be by intention-to-treat, comparing intervention and control clusters, adjusting for compound and trial clustering. This study will provide robust evidence of the effectiveness and cost-effectiveness of community-based participatory learning and action, with integrated health system strengthening and accountability mechanisms, to reduce child mortality. The ethnographic process evaluation will allow for a rich understanding of how the intervention works in this context. However, we encountered a key challenge in calculating the sample size, given the lack of timely and reliable mortality data and the uncertain impacts of the COVID-19 pandemic. ISRCTN 39213655 . Registered on 11 December 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Child mortality remains unacceptably high, with Northern Nigeria reporting some of the highest rates globally (e.g. 192/1000 live births in Jigawa State). Coverage of key protect and prevent interventions, such as vaccination and clean cooking fuel use, is low. Additionally, knowledge, care-seeking and health system factors are poor. Therefore, a whole systems approach is needed for sustainable reductions in child mortality.
METHODS
METHODS
This is a cluster randomised controlled trial, with integrated process and economic evaluations, conducted from January 2021 to September 2022. The trial will be conducted in Kiyawa Local Government Area, Jigawa State, Nigeria, with an estimated population of 230,000. Clusters are defined as primary government health facility catchment areas (n = 33). The 33 clusters will be randomly allocated (1:1) in a public ceremony, and 32 clusters included in the impact evaluation. The trial will evaluate a locally adapted 'whole systems strengthening' package of three evidence-based methods: community men's and women's groups, Partnership Defined Quality Scorecard and healthcare worker training, mentorship and provision of basic essential equipment and commodities. The primary outcome is mortality of children aged 7 days to 59 months. Mortality will be recorded prospectively using a cohort design, and secondary outcomes measured through baseline and endline cross-sectional surveys. Assuming the following, we will have a minimum detectable effect size of 30%: (a) baseline mortality of 100 per 1000 livebirths, (b) 4480 compounds with 3 eligible children per compound, (c) 80% power, (d) 5% significance, (e) intra-cluster correlation of 0.007 and (f) coefficient of variance of cluster size of 0.74. Analysis will be by intention-to-treat, comparing intervention and control clusters, adjusting for compound and trial clustering.
DISCUSSION
CONCLUSIONS
This study will provide robust evidence of the effectiveness and cost-effectiveness of community-based participatory learning and action, with integrated health system strengthening and accountability mechanisms, to reduce child mortality. The ethnographic process evaluation will allow for a rich understanding of how the intervention works in this context. However, we encountered a key challenge in calculating the sample size, given the lack of timely and reliable mortality data and the uncertain impacts of the COVID-19 pandemic.
TRIAL REGISTRATION
BACKGROUND
ISRCTN 39213655 . Registered on 11 December 2019.
Identifiants
pubmed: 35101109
doi: 10.1186/s13063-021-05859-5
pii: 10.1186/s13063-021-05859-5
pmc: PMC8802253
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
95Subventions
Organisme : GSK-Save the Children Partnership
ID : 82603743
Investigateurs
Carina King
(C)
Tim Colbourn
(T)
Rochelle Ann Burgess
(RA)
Agnese Iuliano
(A)
Hamish R Graham
(HR)
Eric D McCollum
(ED)
Tahlil Ahmed
(T)
Samy Ahmar
(S)
Christine Cassar
(C)
Paula Valentine
(P)
Adamu Isah
(A)
Adams Osebi
(A)
Ibrahim Haruna
(I)
Abdullahi Magama
(A)
Ibrahim Seriki
(I)
Temitayo Folorunso Olowookere
(TF)
Matt McCalla
(M)
Adegoke G Falade
(AG)
Ayobami Adebayo Bakare
(AA)
Obioma Uchendu
(O)
Julius Salako
(J)
Funmilayo Shittu
(F)
Damola Bakare
(D)
Omotayo Olojede
(O)
Informations de copyright
© 2021. The Author(s).
Références
Pediatr Pulmonol. 2020 Jun;55 Suppl 1:S78-S90
pubmed: 31990146
PLoS One. 2018 Jan 30;13(1):e0192034
pubmed: 29381745
Lancet. 2013 May 18;381(9879):1736-46
pubmed: 23683640
PLoS Med. 2019 Nov 11;16(11):e1002951
pubmed: 31710601
Eur J Pediatr. 2021 Jul;180(7):2271-2279
pubmed: 33723971
Pediatr Pulmonol. 2020 Jun;55 Suppl 1:S104-S112
pubmed: 31985894
Pediatr Pulmonol. 2020 Jun;55 Suppl 1:S10-S21
pubmed: 31985170
Lancet. 2020 Aug 22;396(10250):519-521
pubmed: 32730743
Health Expect. 2021 Jun;24(3):744-756
pubmed: 33794046
PLoS One. 2016 Dec 28;11(12):e0168743
pubmed: 28030594
Pediatrics. 2020 Dec;146(6):
pubmed: 33144496
Nat Microbiol. 2019 Dec;4(12):2310-2318
pubmed: 31570869
Pediatr Pulmonol. 2020 Jun;55 Suppl 1:S25-S33
pubmed: 31985139
BMC Health Serv Res. 2020 May 8;20(1):392
pubmed: 32384886
Lancet Diabetes Endocrinol. 2019 Mar;7(3):200-212
pubmed: 30733182
PLoS One. 2016 Jan 11;11(1):e0138406
pubmed: 26752726
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Cost Eff Resour Alloc. 2015 Jan 10;13(1):1
pubmed: 25649323
Trials. 2011 Jun 14;12:151
pubmed: 21672223
Trials. 2016 May 04;17(1):232
pubmed: 27142662
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Glob Health Action. 2019;12(1):1597452
pubmed: 31179875
BMC Public Health. 2013 Apr 17;13:354
pubmed: 23590640
Pediatr Infect Dis J. 2020 Dec;39(12):e423-e427
pubmed: 32773660
Lancet Glob Health. 2018 Nov;6(11):e1163-e1175
pubmed: 30309799
Bull World Health Organ. 1973;48(2):183-94
pubmed: 4541684
Glob Health Action. 2017;10(1):1413917
pubmed: 29261449
Lancet Glob Health. 2020 Jul;8(7):e901-e908
pubmed: 32405459
Health Qual Life Outcomes. 2007 Nov 27;5:63
pubmed: 18042300
Med Decis Making. 2012 Mar-Apr;32(2):350-61
pubmed: 22016450
Glob Health Action. 2014 Feb 18;7:23257
pubmed: 24565214